Sterile Compounding in an Unclassified Closet
A Pennsylvania independent pharmacy wants to begin sterile compounding for a local orthopedic practice: 50 prefilled syringes of 0.25% bupivacaine and 100 bags of vancomycin 1 g in 100 mL. The owner has installed a donated horizontal laminar-flow hood in a converted 8-by-10-foot closet with a residential window air conditioner, no HEPA-filtered supply air, no ISO-classified buffer room, no environmental monitoring, and no ante room. Two technicians watched a 30-minute video but have never been glove-tested or media-fill tested. The proposed beyond-use date is 6 months because the products are preservative-free and 'mixed with sterile water.' No stability studies have been done. The practice wants the first batch next week.
1. Can the pharmacy begin producing these sterile preparations next week? Identify the deficiencies and the governing standards.
Read the worked answer
No. The proposed operation does not meet the standards for sterile compounding.
- Sterile compounding is governed by USP General Chapter <797>, which Pennsylvania pharmacy practice standards incorporate. The chapter requires, among other things, an ISO Class 5 primary engineering control located in an ISO Class 7 buffer area with an ISO Class 8 ante area (or a segregated compounding area with strict limitations), HEPA-filtered air, controlled airflow and pressure, cleanable surfaces, and restriction of activities.
- The pharmacy also needs environmental monitoring (nonviable particle counts and viable sampling), personnel qualification (gloved fingertip and thumb sampling, media-fill testing), written SOPs, cleaning and disinfection schedules, gowning and hand hygiene, and a quality program.
- A horizontal laminar-flow hood in a closet with a residential window air conditioner fails nearly every one of these requirements. A horizontal hood also blows air toward the operator, which is inappropriate for many hazardous or patient-contact operations.
- Compounding must be patient-specific or based on a valid anticipatory prescription; large batches for a practice may require a 503B outsourcing facility registration.
- The pharmacy should not begin until the space, equipment, and personnel are qualified.
2. Is a 6-month beyond-use date defensible? How should a BUD be assigned?
Read the worked answer
A 6-month BUD is not defensible on these facts.
- Under USP <797>, a BUD is assigned based on the risk level of the preparation, the method of sterilization, the packaging, the storage conditions, and whether stability and sterility have been validated. Default BUDs for low-risk, medium-risk, and high-risk preparations are specified in the chapter.
- A 6-month BUD generally requires a stability study specific to the drug, concentration, container, and storage condition, plus sterility assurance. 'Preservative-free' and 'sterile water' do not extend a BUD; preservative-free products may actually be more vulnerable to microbial growth.
- The pharmacy has no stability data, no sterility testing, and no environmental monitoring, so it cannot justify an extended BUD.
- The pharmacist should assign only a BUD supported by the applicable default limits and the actual conditions of preparation and storage, and should document the basis.
3. The orthopedic practice says patients need the syringes tomorrow. What lawful options does the pharmacy have?
Read the worked answer
The pharmacy should not dispense these preparations, but it can help the practice obtain them lawfully.
- Refer the practice to a registered 503B outsourcing facility or a hospital pharmacy with a qualified sterile compounding operation that can supply the products with appropriate labeling and BUDs.
- If a genuine emergency exists, the pharmacist may explore the narrow emergency-compounding provisions, but those provisions do not excuse the core requirements of trained personnel, appropriate engineering controls, and sterility assurance. A closet with a donated hood is not an emergency exception.
- The pharmacist should document the referral and the reason the pharmacy declined, and should not release any preparation compounded under the deficient conditions.
- Counseling the practice on the legal and infection-control risks is appropriate; patient safety takes priority over the practice's timeline.